User profiles for Carlos Balmaceda
Carlos Balmaceda AraqueCentre for Health Economics, University of York Verified email at york.ac.uk Cited by 473 |
[HTML][HTML] Impacto de una Política de Equivalencia Terapéutica en el Precio de Medicamentos en Chile
C Balmaceda, MA Espinoza, J Diaz - Value in Health Regional Issues, 2015 - Elsevier
Bioequivalence has become a standard request for drug commercialization in most high
income countries, and significant efforts have been made to implement it in many low and …
income countries, and significant efforts have been made to implement it in many low and …
[PDF][PDF] Gasto de bolsillo en salud y medicamentos en Chile: Análisis comparativo de los periodos 1997, 2007, y 2012
Objectives: Out-of-pocket spent (OPS) of health services are considered inefficient and are
a consequence of inequalities in financing and access. The main objective of this study was …
a consequence of inequalities in financing and access. The main objective of this study was …
Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial
…, JL Briones, F Villarroel-Espindola, C Balmaceda… - PLoS …, 2021 - journals.plos.org
Background Convalescent plasma (CP), despite limited evidence on its efficacy, is being
widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to …
widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to …
[HTML][HTML] Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer
MP Pinto, C Balmaceda, ML Bravo, S Kato… - Gynecologic …, 2018 - Elsevier
Background High-grade serous ovarian cancer (HGSOC) is the most prevalent and aggressive
histologic type of ovarian cancer. To date, there are no reliable biomarkers to effectively …
histologic type of ovarian cancer. To date, there are no reliable biomarkers to effectively …
Enhanced production of resveratrol, piceatannol, arachidin-1, and arachidin-3 in hairy root cultures of peanut co-treated with methyl jasmonate and cyclodextrin
…, L Nopo-Olazabal, C Balmaceda… - Journal of agricultural …, 2015 - ACS Publications
Peanut (Arachis hypogaea) produces stilbenoids upon exposure to abiotic and biotic stresses.
Among these compounds, the prenylated stilbenoids arachidin-1 and arachidin-3 have …
Among these compounds, the prenylated stilbenoids arachidin-1 and arachidin-3 have …
Costs and consequences of chronic pain due to musculoskeletal disorders from a health system perspective in Chile
C Vargas, N Bilbeny, C Balmaceda, MF Rodríguez… - Pain …, 2018 - journals.lww.com
Background: Chronic pain is a prevalent and distressing condition caused by an unceasing
pain lasting more than 3 months or a pain that persists beyond the normal healing time. …
pain lasting more than 3 months or a pain that persists beyond the normal healing time. …
Cost analysis of chronic pain due to musculoskeletal disorders in Chile
…, C Carcamo, P Zitko, P Zamorano, C Balmaceda - PLoS …, 2022 - journals.plos.org
The magnitude of the cost of chronic pain has been a matter of concern in many countries
worldwide. The high prevalence, the cost it implies for the health system, productivity, and …
worldwide. The high prevalence, the cost it implies for the health system, productivity, and …
Analisis del proceso de evaluación de tecnologías sanitarias del sistema de protección financiera para diagnósticos y tratamientos de alto costo en Chile (Ley Ricarte …
…, P Zamorano, D Lahoz, T Yañez, C Balmaceda - Value in Health …, 2022 - Elsevier
Objetivo En Chile la Ley Ricarte Soto define un sistema de protección financiera para
tecnologías sanitarias de alto costo, mediante un proceso de priorización y evaluación de …
tecnologías sanitarias de alto costo, mediante un proceso de priorización y evaluación de …
Early anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: a randomized phase II clinical trial
…, JL Briones, F Villarroel-Espindola, C Balmaceda… - medRxiv, 2020 - medrxiv.org
Background Convalescent plasma (CP), despite limited evidence on its efficacy, is being
widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to …
widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to …
Prevalence, burden of disease, and lost in health state utilities attributable to chronic musculoskeletal disorders and pain in Chile
P Zitko, N Bilbeny, C Balmaceda, T Abbott… - BMC public health, 2021 - Springer
Background Musculoskeletal disorders are a leading cause of disability adjusted life years (DALY)
in the world. We aim to describe the prevalence and to compare the DALYs and loss …
in the world. We aim to describe the prevalence and to compare the DALYs and loss …